Changes in Lp(a), OxPL-apoB, hs-CRP, and IL-6 after acute myocardial infarction (MI) support a pathophysiologic role for Lp(a)-associated OxPLs in myocardial inflammation and highlight the potential for Lp(a) targeted therapies in the early post-MI period.1
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
